Orchestra BioMed Gets $6.1M Milestone Payment After Haemonetics Acquires Vivasure
Orchestra BioMed has received a $6.1 million milestone payment triggered by Haemonetics' acquisition of Vivasure Medical.
Orchestra BioMed has collected a $6.1 million milestone payment following the acquisition of Vivasure Medical by Haemonetics, the company announced via GlobalNewswire. The payment reflects a contractual obligation tied to a defined milestone event stemming from Orchestra BioMed's prior relationship with Vivasure.
Milestone payments of this kind are a common mechanism in medtech and life-sciences deal structures, allowing companies with earlier-stage stakes or partnership agreements to receive proceeds when an acquiring party closes a transaction. For Orchestra BioMed, the payment represents a direct financial return linked to Vivasure's exit via the Haemonetics deal.
Read more C.H. Robinson and Unilever Face Lawsuit Over Serious Crash →
Haemonetics is a global medical technology company with a focus on blood management solutions, and its acquisition of Vivasure Medical brings in capabilities that complement its existing product portfolio. Vivasure, which develops bioabsorbable vascular closure technology, had been a company within Orchestra BioMed's broader ecosystem of cardiovascular innovation partnerships.
The cash infusion gives Orchestra BioMed additional capital at a time when medical device companies continue to face scrutiny over their paths to profitability and commercialization. While the company did not detail how it plans to deploy the funds, milestone receipts like this can support ongoing operations, pipeline development, or balance sheet strengthening.
Continue reading at GlobalNewswire.
